KCB 328

Drug Profile

KCB 328

Alternative Names: KCB

Latest Information Update: 21 Jan 2005

Price : $50

At a glance

  • Originator C&C Research Laboratories
  • Class Class III antiarrhythmics; Small molecules
  • Mechanism of Action Potassium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Preclinical Arrhythmias

Most Recent Events

  • 21 Sep 2004 This compound is still in active development
  • 31 Oct 2002 Chugai Pharmaceutical has been acquired by Roche
  • 11 Sep 1998 A preclinical study has been added to the pharmacodynamics section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top